Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + azacitidine with individualized targeted therapy in newly diagnosed adult AML
ChiCTR2600123561Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonrotoclax in acute myeloid leukemia (AML) (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Composite Complete Remission Rate. Started Apr 2026; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600123561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123561.